IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
A 2026 analyst comparison of biotech AI enablement programs versus one-time AI workshops, covering pricing bands from $2,500 to $250,000, named cases at J&J, AstraZeneca, Sanofi, and Moderna, and FDA/EU AI Act compliance implications.
A 2026 guide to building an AI roadmap for biotech: data readiness, use-case sequencing, FDA/EMA and EU AI Act governance, talent, and 5 named case studies including Roche, Novo Nordisk, and Insilico Medicine.
A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.
A 2026 data-driven benchmark of AI enablement in biotech covering adoption surveys, drug discovery market sizing, FDA/EMA guidance, and five real-world case studies including Insilico Medicine and Isomorphic Labs.
A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.
A 2026 analyst framework mapping biotech and pharma AI adoption across five maturity stages, from shadow AI use to autonomous agentic systems, with governance, GxP validation, and regulatory benchmarks.
Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.
© 2026 IntuitionLabs. All rights reserved.
